---
layout: default
title: 7-Keto-Dehydroepiandrosterone Adenosine Triphospha
parent: 僅模型預測 (L5)
nav_order: 33
evidence_level: L5
indication_count: 0
---

# 7-Keto-Dehydroepiandrosterone Adenosine Triphospha
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This candidate consists of a 16-component mixture including homeopathic ingredients, organ extracts, botanical materials, and conventional molecules (e.g., Insulin Human, Methylcobalamin).
The composition does not correspond to a single drug entity recognised in standard pharmacological databases, and **TxGNN returned no predicted indications**.
As a result, a standard drug repurposing evaluation cannot be completed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None (no TxGNN output) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only (no output produced) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why This Prediction Is Not Available

The candidate identifier resolves to a 16-ingredient mixture rather than a single active pharmaceutical ingredient:

| # | Ingredient | Category |
|---|-----------|---------|
| 1 | 7-Keto-Dehydroepiandrosterone | Endogenous steroid metabolite |
| 2 | Adenosine Triphosphate Disodium | Nucleotide / energy substrate |
| 3 | Echinacea, unspecified | Botanical immunomodulator |
| 4 | Gamboge | Resin / traditional cathartic |
| 5 | Graphite | Homeopathic mineral |
| 6 | Insulin Human | Peptide hormone |
| 7 | Lactic Acid, L- | Organic acid |
| 8 | Methylcobalamin | Vitamin B12 analogue |
| 9 | Phytolacca americana Root | Homeopathic botanical |
| 10 | Pork Kidney | Animal organ extract |
| 11 | Pork Liver | Animal organ extract |
| 12 | Proteus vulgaris | Homeopathic nosode (bacteria) |
| 13 | Strychnos nux-vomica Seed | Homeopathic botanical (alkaloid source) |
| 14 | Sus scrofa Hypothalamus | Porcine organ extract |
| 15 | Sus scrofa Pancreas | Porcine organ extract |
| 16 | Vincetoxicum hirundinaria Root | Homeopathic botanical |

TxGNN is designed to operate on single drug–disease pairs anchored to a DrugBank ID. Because this candidate has no DrugBank ID and is not a unified molecular entity, the model produced no output. Mechanism-of-action analysis is similarly not possible for the mixture as a whole.

---

## Safety Considerations

Please refer to individual ingredient package inserts or regulatory submissions for safety information.

> ⚠️ **Special note**: This mixture contains **Insulin Human**, a high-alert medication with serious hypoglycaemia risk, and **Strychnos nux-vomica** (source of strychnine), which carries a narrow therapeutic index. Any formulation containing these ingredients requires rigorous dose and safety documentation regardless of the overall product classification.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The candidate cannot be evaluated as a drug repurposing candidate because it is a heterogeneous multi-ingredient mixture with no unified pharmacological identity, no DrugBank mapping, no regulatory authorisation, and no TxGNN prediction output.

**To proceed, the following is needed:**

1. **Clarify the evaluable unit** — Identify which single active ingredient within the mixture is the intended repurposing target (e.g., 7-Keto-DHEA or Methylcobalamin independently).
2. **Obtain DrugBank ID** for that single ingredient and re-submit to the TxGNN pipeline.
3. **Determine product classification** — Confirm whether this is a registered homeopathic product, a dietary supplement, or a compounded formulation, as this affects the regulatory pathway.
4. **Obtain full ingredient-level safety data** — particularly for Insulin Human (hypoglycaemia) and Strychnos nux-vomica (strychnine toxicity) components.
5. **Re-run Evidence Pack generation** on the individual active ingredient once identified.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

